Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Viridian Therapeutics Inc (NQ: VRDN ) 22.84 +0.56 (+2.51%) Streaming Delayed Price Updated: 4:00 PM EST, Nov 4, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Viridian Therapeutics Inc < Previous 1 2 3 4 5 6 Next > Analyst Expectations For Viridian Therapeutics's Future October 28, 2024 Via Benzinga Forecasting The Future: 13 Analyst Projections For Viridian Therapeutics September 26, 2024 Via Benzinga Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock September 11, 2024 From Viridian Therapeutics, Inc. Via Business Wire Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock September 10, 2024 From Viridian Therapeutics, Inc. Via Business Wire Critical Insights From Viridian Therapeutics Analyst Ratings: What You Need To Know September 10, 2024 Via Benzinga Decoding 6 Analyst Evaluations For Viridian Therapeutics August 15, 2024 Via Benzinga Calavo Growers Posts Better-Than-Expected Earnings, Joins Tesla, Oracle, Mission Produce And Other Big Stocks Moving Higher On Tuesday September 10, 2024 Via Benzinga Viridian Spikes On A 'Bull-Case Scenario' For Eye Drug Considered Amgen Rival September 10, 2024 The results are also promising for the next-generation version of that drug. Via Investor's Business Daily Viridian Therapeutics Discloses 'Exciting' Data From Experimental Thyroid Eye Disease Candidate, Says Data Met High Bars For Efficacy, Safety September 10, 2024 Viridian Therapeutics announced promising topline data from the THRIVE phase 3 trial of VRDN-001 (veligrotug) for active thyroid eye disease meeting all primary and secondary endpoints. Viridian plans... Via Benzinga Exposures Product Safety Viridian Therapeutics Announces Positive Topline Results from Veligrotug (VRDN-001) Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease September 10, 2024 From Viridian Therapeutics, Inc. Via Business Wire Expert Ratings For Viridian Therapeutics July 16, 2024 Via Benzinga 7 Analysts Assess Viridian Therapeutics: What You Need To Know June 06, 2024 Via Benzinga Why Oracle Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket September 10, 2024 Via Benzinga Viridian Therapeutics to Webcast VRDN-001 Phase 3 THRIVE Topline Results on September 10, 2024 September 09, 2024 From Viridian Therapeutics, Inc. Via Business Wire Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) September 05, 2024 From Viridian Therapeutics, Inc. Via Business Wire VRDN Stock Earnings: Viridian Therapeutics Misses EPS, Misses Revenue for Q2 2024 August 08, 2024 VRDN stock results show that Viridian Therapeutics missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. Via InvestorPlace Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2024 Financial Results August 08, 2024 From Viridian Therapeutics, Inc. Via Business Wire Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) August 07, 2024 From Viridian Therapeutics, Inc. Via Business Wire Top 3 Health Care Stocks You May Want To Dump This Quarter July 30, 2024 Via Benzinga Viridian Therapeutics Announces Completion of THRIVE-2 Enrollment for VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED) July 25, 2024 From Viridian Therapeutics, Inc. Via Business Wire Biogen Has Up To $10 Billion For Acquisitions; Why These Three Names Make Sense July 16, 2024 Biogen has $8 billion to $10 billion in dry powder for acquisitions. Here are three names the company could examine. Via Investor's Business Daily 3 Small-Cap Stocks With Explosive 2X Growth Potential July 08, 2024 Discover three top high-growth small-cap stocks, fueled by potential rate cuts and promising prospects in the second half of 2024. Via InvestorPlace Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) July 03, 2024 From Viridian Therapeutics, Inc. Via Business Wire 12 Health Care Stocks Moving In Tuesday's Pre-Market Session June 11, 2024 Via Benzinga Viridian Therapeutics Announces Details of Subcutaneous VRDN-003 Phase 3 Clinical Program for Patients with Active and Chronic Moderate-to-Severe Thyroid Eye Disease June 11, 2024 From Viridian Therapeutics, Inc. Via Business Wire Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) June 06, 2024 From Viridian Therapeutics, Inc. Via Business Wire Viridian Therapeutics Announces Participation in Upcoming June Investor Conferences May 31, 2024 From Viridian Therapeutics, Inc. Via Business Wire Viridian Therapeutics to Participate in Upcoming May Investor Conferences May 10, 2024 From Viridian Therapeutics, Inc. Via Business Wire VRDN Stock Earnings: Viridian Therapeutics Beats EPS, Beats Revenue for Q1 2024 May 08, 2024 VRDN stock results show that Viridian Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. Via InvestorPlace Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2024 Financial Results May 08, 2024 From Viridian Therapeutics, Inc. Via Business Wire < Previous 1 2 3 4 5 6 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
